Andre Henri Goy MD

Dr. Andre Goy, MD. MS. is chairman and director, chief of Lymphoma, and director of Clinical and Translational Cancer Research at the John Theurer Cancer Center at HackensackUMC, a member of Hackensack Meridian Health. He also serves as the Lydia Pfund chair for Lymphoma at the Seton Hall-Hackensack Meridian School of Medicine, chief science officer of Regional Cancer Care Associates, and professor of medicine at Georgetown University.

Dr. Goy is widely-known for his work in mantle cell lymphoma where he was the lead investigator for the development of the three FDA approved drugs in the U.S. for mantle cell lymphoma: from the first proteasome inhibitor bortezomib (Velcade) in 2006, to the first immunomodulator lenalidomide (Revlimid) in 2013 and the first BTK inhibitor ibrutinib (Imbruvica) in 2013 as well. He also participated in the pilot study for the first anti-CD20 monoclonal antibody approved in blood cancers: rituximab (Rituxan), which has had a profound impact in the management of B-cell lymphoma and leukemia as well as autoimmune disorders.

Dr. Goy’s interest as a lymphoma researcher focuses on novel therapies and new strategies to improve the outcome of lymphoma patients. He is currently leading numerous trials using novel agents or combinations in lymphomas including new monoclonal antibodies, Bcl-2 inhibitors and second generation kinase inhibitors among others. He is also working with his team exploring new non–chemotherapy options in certain subtypes of lymphoma.